Richard Wayne Joseph
196 works · 24,484 citations · h-index 49
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- High response rate to PD-1 blockade in desmoplastic melanomas
- Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
- Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy